Compare BRID & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRID | ACOG |
|---|---|---|
| Founded | 1932 | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Specialty Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.8M | 115.5M |
| IPO Year | N/A | N/A |
| Metric | BRID | ACOG |
|---|---|---|
| Price | $7.69 | $6.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 2.8K | ★ 104.8K |
| Earning Date | 01-28-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $227,364,000.00 | $7,427,199.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $132.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.24 | $3.75 |
| 52 Week High | $10.83 | $11.54 |
| Indicator | BRID | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 55.95 |
| Support Level | $7.26 | $5.61 |
| Resistance Level | $8.50 | $6.20 |
| Average True Range (ATR) | 0.25 | 0.57 |
| MACD | -0.06 | 0.10 |
| Stochastic Oscillator | 32.26 | 74.00 |
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The business segments are; the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, and mass merchandise and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.